These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 20413322)
1. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Ansari RH; Socinski MA; Edelman MJ; Belani CP; Gonin R; Catalano RB; Marinucci DM; Comis RL; Obasaju CK; Chen R; Monberg MJ; Treat J; Crit Rev Oncol Hematol; 2011 May; 78(2):162-71. PubMed ID: 20413322 [TBL] [Abstract][Full Text] [Related]
2. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK; Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506 [TBL] [Abstract][Full Text] [Related]
3. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Treat JA; Gonin R; Socinski MA; Edelman MJ; Catalano RB; Marinucci DM; Ansari R; Gillenwater HH; Rowland KM; Comis RL; Obasaju CK; Belani CP; Ann Oncol; 2010 Mar; 21(3):540-547. PubMed ID: 19833819 [TBL] [Abstract][Full Text] [Related]
4. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K; Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004. Saito H; Nakagawa K; Takeda K; Iwamoto Y; Ando M; Maeda M; Katakami N; Nakano T; Kurata T; Fukuoka M Am J Clin Oncol; 2012 Feb; 35(1):58-63. PubMed ID: 21293243 [TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123 [TBL] [Abstract][Full Text] [Related]
8. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Edelman MJ; Gandara DR; Lau DH; Lara P; Lauder IJ; Tracy D Cancer; 2001 Jul; 92(1):146-52. PubMed ID: 11443620 [TBL] [Abstract][Full Text] [Related]
9. A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer. Obasaju CK; Ansari RH; Socinski MA; Chen R; Monberg MJ; Catalano RB; Marinucci DM; Liles DK; Ribeiro MJ; Comis RL; Treat J; J Thorac Oncol; 2010 Jul; 5(7):993-1000. PubMed ID: 20593535 [TBL] [Abstract][Full Text] [Related]
10. Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer. Minami S; Kijima T; Shiroyama T; Okafuji K; Hirashima T; Uchida J; Imamura F; Osaki T; Nakatani T; Ogata Y; Yamamoto S; Namba Y; Otsuka T; Tachibana I; Komuta K; Kawase I BMC Res Notes; 2013 Jan; 6():3. PubMed ID: 23281805 [TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. Langer C; Li S; Schiller J; Tester W; Rapoport BL; Johnson DH; J Clin Oncol; 2007 Feb; 25(4):418-23. PubMed ID: 17264337 [TBL] [Abstract][Full Text] [Related]
12. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer. Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386 [TBL] [Abstract][Full Text] [Related]
13. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Greco FA; Spigel DR; Kuzur ME; Shipley D; Gray JR; Thompson DS; Burris HA; Yardley DA; Pati A; Webb CD; Gandhi JG; Hainsworth JD Clin Lung Cancer; 2007 Sep; 8(8):483-7. PubMed ID: 17922972 [TBL] [Abstract][Full Text] [Related]
14. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study. Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491 [TBL] [Abstract][Full Text] [Related]
15. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial. Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792 [TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer. Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822 [TBL] [Abstract][Full Text] [Related]
17. Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer. Sovak MA; Lutzker S; Zheng L; Guensch L; Joyce M; Schwartz S; Wu Y; Aisner J Lung Cancer; 2006 Aug; 53(2):177-81. PubMed ID: 16790293 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer. Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer. Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer. Xu N; Shen P; Zhang XC; Yu LF; Bao HY; Shi GM; Huang S; Chen J; Mou HB; Fang WJ Cancer Chemother Pharmacol; 2007 Jan; 59(1):1-7. PubMed ID: 16614849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]